1-(3,5-dimethoxy-phenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-phenyl]-urea | 936099-46-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3,5-dimethoxy-phenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)-phenyl]-urea
• 英文别名: 1-(3,5-dimethoxyphenyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]urea
• CAS: 936099-46-6
• 化学式: C₂₁H₁₉N₅O₄
• 分子量: 405.413
• InChiKey: LICCVFXPSLEQPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION
  申请人：Wang Weidong

  公开号：US20100130476A1

  公开（公告）日：2010-05-27

  The present invention relates to compounds and compositions for inducing the expansion of pancreatic β-cells. The invention further relates to a use of these expanded pancreatic β-cells to reversibly expand pancreatic β-cells and other quiescent cells to overcome deficits associated with degenerative and/or autoimmune diseases.

  本发明涉及用于诱导胰岛素β细胞扩张的化合物和组合物。该发明进一步涉及利用这些扩张的胰岛素β细胞来可逆地扩张胰岛素β细胞和其他静止细胞，以克服与退行性和/或自身免疫疾病相关的缺陷。
• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP1940844B1

  公开（公告）日：2009-09-30
• US8592433B2
  申请人：——

  公开号：US8592433B2

  公开（公告）日：2013-11-26
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DES KINASES DES PROTEINES
  申请人：IRM LLC

  公开号：WO2007053343A2

  公开（公告）日：2007-05-10

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-Abl, Aurora- A, AxI, BMX, CHK2, c-RAF, cSRC, Fes, FGFR3, Flt3, IKKa, IR, JNK2a2, Lck, Met, MKK6, MST2, p70S6K, PDGFRa, PKA, PKD2, ROCK-II, Ros, Rskl, SAPK2a, SAPK2ß, SAPK3 SAPK4, Syk, Tie2 and TrkB kinases.
  [FR] L'invention concerne une nouvelle classe de composés, des compositions pharmaceutiques qui comprennent ces composés et des procédés d'utilisation de ces composés pour traiter ou prévenir des maladies ou des affections associés à une activité anormale ou dérégulée des kinases et en particulier les maladies ou affections associés à une activation anormale des kinases d'AbI, de Bcr-Abl, d'Aurora-A, d'AxI, de BMX, de CHK2, de c-RAF, de cSRC, de Fes, de FGFR3, de Flt3, d'IKKa, d'IR, de JNK2a2, de Lck, de Met, de MKK6, de MST2, de p70S6K, de PDGFRa, de PKA, de PKD2, de ROCK-II, de Ros, de Rskl, de SAPK2a, de SAPK2ß, de SAPK3, de SAPK4, de Syk, de Tie2 et de TrkB.
• [EN] PREVENTION AND TREATMENT OF CANCER WITH RAS GENE MUTATION<br/>[FR] PRÉVENTION ET TRAITEMENT D'UN CANCER AVEC MUTATION DU GÈNE RAS
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010036917A1

  公开（公告）日：2010-04-01

  The present invention relates to a method to prevent or treat cancer with RAS gene mutation by administering a EGFR/ErbB2 tyrosine kinase inhibitor, which has grater effect than conventional EGFR/ErbB2 tyrosine kinase inhibitors, or the salt or prodrug thereof to a mammal, a pharmaceutical composition containing at least the EGFR/ErbB2 tyrosine kinase inhibitor for treating or preventing cancer with RAS gene mutation, use of the EGFR/ErbB2 tyrosine kinase inhibitor for preparing the pharmaceutical composition for treating or preventing cancer with RAS gene mutation.